New MANF research on use as a biomarker for DN fro
Post# of 30066
(Total Views: 77)
Posted On: 06/04/2025 2:10:26 PM
.jpg)
New MANF research on use as a biomarker for DN from Turkey.
The Role of Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) in Biomarkers of Diabetic Nephropathy
Year 2025, Volume: 11 Issue: 2, 65 - 69, 27.05.2025
Kağan Tur , Kenan Güçlü
https://doi.org/10.30934/kusbed.1653929
Abstract
Objective: This study investigates the potential role of Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) as a novel biomarker, evaluating its associations with established urinary biomarkers and glycemic control indicators in diabetes mellitus and diabetic nephropathy (DN).
Methods: A cross-sectional study was conducted involving 84 participants stratified by albuminuria levels into normoalbuminuria, microalbuminuria, and macroalbuminuria groups. MANF levels were quantified using enzyme-linked immunosorbent assays (ELISA), while urinary biomarkers and HbA1C were measured using standard clinical methods. Correlation analyses and multivariate regression models were employed to assess relationships between MANF and biomarkers.
Results: MANF levels demonstrated a significant upward trend across albuminuria categories, with the highest levels observed in the macroalbuminuria group (514.5±112.3 pg/mL, p<0.01). MANF positively correlated with HbA1C (R=0.78, p<0.001) and negatively with estimated glomerular filtration rate (eGFR) (R=0.72, p<0.001). These associations remained significant after adjusting for confounders such as age, sex, and body mass index (BMI).
Conclusion: MANF is a promising biomarker that reflects glycemic dysregulation and renal dysfunction, offering potential advantages over traditional markers. Its integration into clinical practice could enhance the early detection and personalized management of chronic kidney disease (CKD) and diabetes. Future longitudinal studies are warranted to validate its predictive value.
https://dergipark.org.tr/en/pub/kusbed/issue/92056/1653929
The Role of Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) in Biomarkers of Diabetic Nephropathy
Year 2025, Volume: 11 Issue: 2, 65 - 69, 27.05.2025
Kağan Tur , Kenan Güçlü
https://doi.org/10.30934/kusbed.1653929
Abstract
Objective: This study investigates the potential role of Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) as a novel biomarker, evaluating its associations with established urinary biomarkers and glycemic control indicators in diabetes mellitus and diabetic nephropathy (DN).
Methods: A cross-sectional study was conducted involving 84 participants stratified by albuminuria levels into normoalbuminuria, microalbuminuria, and macroalbuminuria groups. MANF levels were quantified using enzyme-linked immunosorbent assays (ELISA), while urinary biomarkers and HbA1C were measured using standard clinical methods. Correlation analyses and multivariate regression models were employed to assess relationships between MANF and biomarkers.
Results: MANF levels demonstrated a significant upward trend across albuminuria categories, with the highest levels observed in the macroalbuminuria group (514.5±112.3 pg/mL, p<0.01). MANF positively correlated with HbA1C (R=0.78, p<0.001) and negatively with estimated glomerular filtration rate (eGFR) (R=0.72, p<0.001). These associations remained significant after adjusting for confounders such as age, sex, and body mass index (BMI).
Conclusion: MANF is a promising biomarker that reflects glycemic dysregulation and renal dysfunction, offering potential advantages over traditional markers. Its integration into clinical practice could enhance the early detection and personalized management of chronic kidney disease (CKD) and diabetes. Future longitudinal studies are warranted to validate its predictive value.
https://dergipark.org.tr/en/pub/kusbed/issue/92056/1653929
(2)
(0)